Peptides for Energy: What the Evidence Shows in 2026
We found no controlled trial showing that any peptide raises energy in healthy people. The best-tested one, SS-31 (elamipretide), missed its fatigue endpoint in a 24-week, 218-person trial in primary mitochondrial myopathy, and its only FDA approval is for Barth syndrome. MOTS-c has mouse performance data and no fatigue trial in people that we found, and injected NAD+ has no fatigue trial that we found either. Iron deficiency, thyroid disease, sleep problems and some medicines explain far more tiredness than mitochondria do, so check those first.
Updated 2 November 2026. Every study, regulatory and number claim on this page is tied to a source in the list at the end, checked 2 November 2026. Research use framing: this reports what trials and regulators say, it is not advice.
Rule Out the Common Causes First
Best vendor for SS-31 right now: Amino Club
20mg vial, $79.99 per vial ($4.00 per mg), list price checked 2026-09-08. The vendor Bureau readers order from most this year, with a batch COA on every product page. Partner code 100 at checkout takes 20% off there, and keeps the order counted for the Bureau. Research use only.
Check price at Amino Club Compare all vendors Black FridayCyber Monday 40% off, applied by our link (was 20%) code 100 ends 30 NovFatigue is a symptom, not a diagnosis, and the person who is tired because their mitochondria make less ATP is a small slice of the people who are tired. The NHS advises seeing a GP if you have been tired for a few weeks without knowing why. Iron matters even without anaemia: a pooled analysis of 18 randomized trials enrolling 1,170 non-anaemic iron-deficient adults found that iron supplementation lowered self-reported fatigue (standardised mean difference -0.38, 95% CI -0.52 to -0.23, from 4 trials with 714 participants), while objective measures such as VO2max did not change. We found no peptide with a pooled result like that.
| Cause | What the health sources say |
|---|---|
| Iron deficiency | Tiredness and lack of energy are listed symptoms of iron deficiency anaemia, usually checked with a full blood count (NHS). In iron-deficient adults without anaemia, iron lowered self-reported fatigue (SMD -0.38, 4 trials, 714 people) but did not change VO2max (BMJ Open 2018). |
| Underactive thyroid | Fatigue is listed among common symptoms of hypothyroidism, and doctors may use thyroid blood tests and imaging tests to confirm it (NIDDK). |
| Sleep apnoea and poor sleep | Daytime sleepiness and tiredness are listed symptoms of sleep apnea (NHLBI). |
| Anaemia, diabetes, overactive thyroid | The NHS says you may need blood tests to check for anaemia, diabetes or an overactive thyroid if you have been tired for a few weeks without knowing why. |
| Medicines, including GLP-1 drugs | On the Wegovy label, fatigue (including asthenia) was reported by 11% of 2,116 adults on 2.4 mg against 5% of 1,261 on placebo. |
| ME/CFS | A clinical diagnosis: reduced activity for more than 6 months, post-exertional malaise and unrefreshing sleep, plus orthostatic intolerance or cognitive impairment (CDC). |
Calculate your draw for any compound on this page
Pick the peptide, enter your vial, water and dose, and get the exact syringe mark plus doses per vial. Twenty-seven compounds, free, no signup.
Open the peptide calculator peptulator.com, the Bureau's independent toolIf those have been checked and the tiredness is still unexplained, the mitochondrial argument becomes worth weighing. If they have not been checked, nothing below is the right next step. If poor sleep is the pattern, the sleep peptides page covers that side.
Peptides for Energy Compared: Evidence and US Status
| Compound | Proposed route to energy | Human evidence on fatigue or energy | US status |
|---|---|---|---|
| SS-31 (elamipretide) | Binds cardiolipin in the inner mitochondrial membrane | MMPOWER-3: 218 adults with primary mitochondrial myopathy, 40 mg a day for 24 weeks, no benefit over placebo on 6-minute walk or total fatigue score | FDA accelerated approval (Forzinity) for Barth syndrome only |
| MOTS-c | Mitochondria-encoded peptide; AMPK activation through the folate cycle | Mouse performance data. In people, exercise raises its own levels; no treatment trial with a fatigue outcome found | One of six peptides in the 30 October 2026 HHS interim 503A policy, which is not an approval |
| NAD+ and precursors (NMN, NR) | Raise NAD+, a coenzyme in energy metabolism | Oral NR raised NAD+; oral NMN 250 mg for 12 weeks improved sit-to-stand and drowsiness, with placebo groups improving too. No trial of injected NAD+ for fatigue found | Not among the six HHS peptides |
| Epitalon | Pineal tetrapeptide; proposed melatonin and telomerase effects | No fatigue or energy trial found; a 2025 overview describes in vitro, in vivo and in silico work | One of the six HHS peptides (injection, intermittent courses); not an approval |
| Semax | ACTH(4-10) analogue; raised BDNF protein in rat brain | Rodent data; no fatigue trial found | One of the six HHS peptides (intranasal only); not an approval |
| Selank | Proposed GABA-system effects | A 2017 paper cites clinical studies of an anxiolytic effect; its own cell data showed no direct change in GABA gene expression; no fatigue trial found | Not among the six HHS peptides; listed as a withdrawn nomination on FDA's 22 April 2026 page |
The pattern in the table is the answer to the main question: the compounds with the best mechanism stories have the least human fatigue data, and the one with a randomized fatigue endpoint did not meet it.
MOTS-c: A Mitochondrial Peptide With Mouse Data
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA rather than nuclear DNA. In mouse and cell work it inhibits the folate cycle and the purine synthesis tied to it, which activates AMPK, the same energy-sensing pathway that exercise engages, and skeletal muscle appears to be its main target organ (Cell Metabolism, 2015). The MOTS-c guide has the full detail.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutesThe performance data are from mice. In a 2021 Nature Communications paper, MOTS-c improved physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice, and late-life treatment three times a week increased physical capacity and healthspan; in people, exercise raised MOTS-c expression in skeletal muscle and in circulation. That is a mouse result plus a measurement of the peptide's own levels in people, not a trial of MOTS-c as a treatment. A 2023 review adds that MOTS-c concentration decreases with age but that its levels across health conditions "remain controversial", and a 2022 pilot study found lower serum MOTS-c in 75 professional endurance athletes than in 30 sedentary controls, so a higher level is not simply a sign of fitness.
The MOTS-c benefits page goes through the evidence behind each claim, and the side effects page covers the safety record. It is also one of the six peptides in the 30 October 2026 HHS interim 503A policy, which HHS describes as an enforcement policy, not an approval.
Get the Dispatch
One research note, one vendor deal, once a week. Free dosing guide on confirm.
Double opt-in. Unsubscribe with one click. Research use only.
SS-31 (Elamipretide): The Best-Tested Option
SS-31 is elamipretide, which the FDA label describes as a mitochondrial cardiolipin binder. That is the mechanism claim behind its use in mitochondrial disease.
The trial that matters for this page is MMPOWER-3. It randomised 218 adults with genetically confirmed primary mitochondrial myopathy to 40 mg a day of subcutaneous elamipretide or placebo for 24 weeks, with 6-minute walk distance and the total fatigue score on the Primary Mitochondrial Myopathy Symptom Assessment as the two primary endpoints. It met neither. The walk-distance difference was -3.2 m (95% CI -18.7 to 12.3, p = 0.69) and the fatigue score difference had p = 0.37; the paper classed this as Class I evidence that elamipretide does not improve the walk test or fatigue at 24 weeks in this population. It was well tolerated.
The approved use is narrower still. Forzinity (elamipretide), at 40 mg subcutaneously once daily, is indicated to improve muscle strength in patients with Barth syndrome who weigh at least 30 kg. That is an accelerated approval based on knee extensor muscle strength, an intermediate endpoint, and continued approval may depend on a confirmatory trial. The label's safety data come from 12 male patients aged 12 to 35 years. We found no trial of SS-31 in otherwise healthy people. The SS-31 page covers the full trial record.
NAD+ and the Precursor Question
NAD+ is a coenzyme, and NAD+ precursors have been proposed as a way to improve function with ageing. The human trials are of oral precursors, and they measure other things. In a crossover trial of two 6-week periods in healthy middle-aged and older adults, nicotinamide riboside was well tolerated and raised NAD+; the authors suggested later trials look at blood pressure and arterial stiffness. In a 12-week trial of 108 older adults, 250 mg of NMN a day improved the five-times sit-to-stand test and drowsiness, with the largest effect sizes (d = 0.72 and 0.64) in the afternoon NMN group, but placebo groups improved too, all groups on sit-to-stand and the afternoon placebo group on drowsiness.
Whether injecting NAD+ itself beats a precursor is the unresolved part. In human cell experiments, extracellular NMN was converted by the cell-surface enzyme CD73 to nicotinamide riboside, which the cells used for intracellular NAD+ synthesis, so precursors may be processed outside the cell before use; a separate 2008 study found two mammalian cell types transported low NAD concentrations effectively. We did not find a randomized trial of injected NAD+ with a fatigue outcome. The NAD+ injection dosage page covers the reported injection protocols.
Epitalon: An Indirect Argument Through Sleep
Epitalon, also written epithalon, is the tetrapeptide Ala-Glu-Asp-Gly, built from the amino acid composition of epithalamin, a bovine pineal extract. A 2025 overview says it has been studied for about 25 years in vitro, in vivo and in silico, that it influences melatonin synthesis and telomerase activity, and that it remains uncertain whether those are its only mechanisms. The energy argument is indirect, running through sleep and the pineal axis, and we found no fatigue trial. It is one of the six peptides named in the 30 October 2026 HHS interim policy, for subcutaneous or intramuscular injection dispensed in intermittent courses. The epithalon page covers what the original work reported.
The two with the clearest mitochondrial rationale
MOTS-c for the AMPK pathway, SS-31 for cardiolipin. Both listed as direct products by Pantheon, scored in the 2026 scorecard.
Pantheon MOTS-C Pantheon EpithalonPeptides for Energy and Focus: Semax and Selank
These are the compounds people recommend when "energy" means focus rather than stamina. The data are rodent and cell data. Semax, an ACTH(4-10) analogue, raised BDNF protein in the basal forebrain of rats three hours after intranasal dosing, and in another rodent study it raised a striatal serotonin metabolite and enhanced amphetamine-induced dopamine release without changing dopamine on its own. For selank, a 2017 paper cites clinical studies of an anxiolytic effect comparable to benzodiazepines, then found no direct change in GABA-system gene expression in a neuroblastoma cell line.
None of that is a mitochondrial or energy-production mechanism. A reported effect would be on attention or anxiety, and that matters if the tiredness has a physical cause: it can change how tired you feel without touching the cause. Semax is one of the six peptides in the HHS interim policy, for intranasal use only; selank is not. The semax page and the selank page cover each in detail.
How To Approach This
- Test first. The NHS names anaemia, diabetes and an overactive thyroid as things a blood test can check for in unexplained tiredness. Fix what turns up before adding anything.
- Change one thing at a time. Starting three compounds together means no change can be attributed to any of them, and the placebo groups in the NMN trial improved on several measures.
- Set a measurable endpoint first. The trials above used validated fatigue scales and timed tests such as the 6-minute walk and the five-times sit-to-stand, not impressions.
- Judge over weeks, not days. The trials with fatigue or related outcomes ran 12 and 24 weeks. No source we found gives a time to effect for any peptide.
- Set expectations from the trials. The one randomized peptide trial with a fatigue endpoint on this page was negative.
If the goal is a structured protocol rather than a single compound, the stack builder lays out selection and timing, and the longevity page covers the overlapping compound set.
Key Takeaways
- We found no controlled trial showing that any peptide raises energy in healthy people
- SS-31 missed its fatigue endpoint in MMPOWER-3 (218 adults, 24 weeks), and its only approval is for Barth syndrome
- MOTS-c has mouse performance data and no fatigue trial in people that we found
- Human NAD+ trials are of oral precursors; injected NAD+ has no fatigue trial that we found
- Epitalon, semax and selank have no fatigue trial that we found; semax and selank act on attention and anxiety, not energy production
- Iron deficiency without anaemia has a pooled trial result for fatigue (4 trials, 714 people); no peptide on this page does
See also: what the SLU-PP-332 mouse studies show.
Frequently Asked Questions
What is the best peptide for energy?
There is no proven best peptide for energy. SS-31 (elamipretide) has the most human trial data, but its 218-person trial in primary mitochondrial myopathy missed its fatigue endpoint at 24 weeks, and its only FDA approval is for Barth syndrome. MOTS-c has a well described mechanism and mouse performance data but no fatigue trial in people that we found. Checking for iron deficiency, thyroid problems and sleep disorders comes first.
Does MOTS-c increase energy?
It improved physical performance in young, middle-aged and old mice, and exercise raises MOTS-c in human muscle and blood. That does not show that taking it raises energy in people, and we found no human treatment trial of MOTS-c with a fatigue outcome. A pilot study also found lower serum MOTS-c in 75 professional endurance athletes than in 30 sedentary controls, so higher levels are not simply a marker of fitness.
Does SS-31 help with fatigue?
In the one large randomized trial with a fatigue endpoint, no. MMPOWER-3 gave 40 mg a day or placebo to 218 adults with primary mitochondrial myopathy for 24 weeks and found no difference in total fatigue score (p = 0.37) or in 6-minute walk distance (p = 0.69). The FDA approval is for muscle strength in Barth syndrome, not for fatigue.
Is injectable NAD+ better than oral NMN?
Nobody has shown that. The human trials are of oral precursors: nicotinamide riboside raised NAD+ in a crossover trial of two 6-week periods, and NMN at 250 mg a day for 12 weeks improved sit-to-stand time and drowsiness in older adults, although the placebo groups improved too. Cell studies point both ways on how extracellular NAD+ and its precursors reach the inside of cells, and we found no randomized trial of injected NAD+ for fatigue.
Do semax and selank help with fatigue?
They are studied for attention, memory and anxiety, not for energy production. Semax raised BDNF protein in rat brain, and a 2017 paper cites clinical studies of an anxiolytic effect for selank, but we found no fatigue trial for either. If the tiredness comes from anaemia, an underactive thyroid or poor sleep, a change in how tired you feel does not fix the cause.
How long does it take for an energy peptide to work?
No source we found gives a time to effect for any peptide in fatigue. The trials with fatigue or related outcomes ran 12 weeks (NMN) and 24 weeks (elamipretide), and the placebo groups in the NMN trial improved on several measures, so an impression after a week or two says little.
What should I check before trying a peptide for fatigue?
The NHS advises seeing a GP if you have been tired for a few weeks without knowing why, and says blood tests may check for anaemia, diabetes or an overactive thyroid. An underactive thyroid and sleep apnoea also list fatigue or daytime sleepiness as symptoms. In non-anaemic iron-deficient adults, iron supplementation lowered self-reported fatigue in a pooled analysis of 4 trials with 714 participants.
Can peptides treat chronic fatigue syndrome (ME/CFS)?
We found no trial of any peptide on this page in ME/CFS. The CDC describes ME/CFS as a reduced ability to do pre-illness activities for more than 6 months, with post-exertional malaise and unrefreshing sleep, plus orthostatic intolerance or cognitive impairment. That is a diagnosis for a clinician to make.
Sources (checked 2 November 2026)
- NHS, Tiredness and fatigue. nhs.uk. Checked 2 November 2026.
- NHS, Iron deficiency anaemia. nhs.uk. Checked 2 November 2026.
- Houston BL, et al. Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults: a systematic review of randomised controlled trials. BMJ Open, 2018. PMID 29626044. Checked 2 November 2026.
- NIDDK, Hypothyroidism (underactive thyroid). niddk.nih.gov. Checked 2 November 2026.
- NHLBI, Sleep apnea: symptoms. nhlbi.nih.gov. Checked 2 November 2026.
- Wegovy (semaglutide) injection prescribing information, Novo Nordisk, DailyMed (label published 30 June 2026), adverse reactions table for adults with obesity or overweight. DailyMed. Checked 2 November 2026.
- CDC, Clinical overview of ME/CFS: diagnostic criteria. cdc.gov. Checked 2 November 2026.
- Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology, 2023 (NCT03323749). PMID 37268435. Checked 2 November 2026.
- FORZINITY (elamipretide) prescribing information, Stealth BioTherapeutics, DailyMed (label dated 10 December 2025): indication, dosage, adverse reactions. DailyMed. Checked 2 November 2026.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015. PMID 25738459. Checked 2 November 2026.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021. PMID 33473109. Checked 2 November 2026.
- Wan W, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. Journal of Translational Medicine, 2023;21:36. PMC9854231. Checked 2 November 2026.
- Alser M, et al. The effect of chronic endurance exercise on serum levels of MOTS-c and humanin in professional athletes. Reviews in Cardiovascular Medicine, 2022. PMC11273660. Checked 2 November 2026.
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 2018. PMID 29599478. Checked 2 November 2026.
- Kim M, et al. Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults: a randomized, double-blind placebo-controlled study. Nutrients, 2022. PMID 35215405. Checked 2 November 2026.
- Grozio A, et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. Journal of Biological Chemistry, 2013. PMID 23880765. Checked 2 November 2026.
- Billington RA, et al. Characterization of NAD uptake in mammalian cells. Journal of Biological Chemistry, 2008. PMID 18180302. Checked 2 November 2026.
- Araj SK, et al. Overview of epitalon: highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 2025. PMID 40141333. Checked 2 November 2026.
- Dolotov OV, et al. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. Journal of Neurochemistry, 2006. PMID 16635254. Checked 2 November 2026.
- Eremin KO, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 2005. PMID 16362768. Checked 2 November 2026.
- Filatova E, et al. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Frontiers in Pharmacology, 2017. PMID 28293190. Checked 2 November 2026.
- HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Federal Register notice 2026-22192, 91 FR 68526, 30 October 2026. The notice refers to Appendix A without naming the peptides. federalregister.gov. Checked 2 November 2026.
- BakerHostetler, HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, 28 October 2026: names the six peptides and their routes. The HHS appendix PDF itself could not be opened on 2 November 2026. bakerlaw.com. Checked 2 November 2026.
- FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of 22 April 2026): selank listed among withdrawn nominations. fda.gov. Checked 2 November 2026.
Not sure which of these you actually need?
Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.
Build your stack, 2 minutes